Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI, Inc. (OTCQX: PYNKF) is a commercial-stage medical technology company whose news flow centers on the development, clinical use, and commercialization of its optical coherence tomography (OCT) imaging platforms for cancer surgery. Company updates frequently highlight the adoption of its FDA-cleared Perimeter S-Series OCT system in operating rooms across the United States, including agreements with major health systems and hospitals for tissue visualization during surgery.
News releases describe how surgeons at leading centers are using the S-Series OCT to obtain real-time, cross-sectional visualization of excised tissues at the cellular level, and how this imaging can provide additional insights for intraoperative decision-making. Perimeter also reports on progress with its investigational Perimeter B-Series OCT with Assist AI, a breakthrough-device-designated platform that combines OCT with artificial intelligence and has been evaluated in a pivotal clinical trial supported by a grant from the Cancer Prevention and Research Institute of Texas.
Investors following PYNKF can expect updates on commercial traction for the S-Series, including new hospital installations and systemwide agreements, as well as regulatory milestones related to the B-Series PMA review. The company’s news also covers participation in professional medical conferences, breast surgery forums, and investor events, along with capital raising activities intended to support commercialization and product development.
This news page aggregates Perimeter’s press releases and related coverage so readers can monitor developments in its OCT imaging technology, clinical collaborations, regulatory pathway, and corporate strategy. For those tracking small- and micro-cap medical technology names, the PYNKF news feed offers ongoing insight into how Perimeter is positioning its imaging platforms within cancer surgery and breast care.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has successfully placed its Perimeter S-Series OCT system in a major North Texas healthcare network hospital. This marks a significant step in validating their commercial model, highlighting their commitment to enhancing cancer surgery outcomes with advanced imaging technology. The Perimeter S-Series OCT offers real-time, high-resolution tissue visualization, aiming to reduce healthcare costs. CEO Jeremy Sobotta expressed enthusiasm about the system's potential impact on patient care and the interest from top surgeons.
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) reported its second quarter results on August 24, 2022. The company anticipates 10-20 commercial installations for its S-Series OCT device, reflecting increased market opportunities. Operating expenses amounted to $6.3 million, up from $3.1 million a year prior, while the net loss narrowed to $366,296 compared to $3.2 million in Q2 2021. Cash and cash equivalents stood at $44.97 million. The company is progressing in its pivotal clinical trial for the B-Series OCT system, with seven out of eight sites activated.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) will announce its second quarter 2022 financial results after U.S. markets close on August 24, 2022. A conference call is scheduled for the same day at 5:00 PM ET, featuring key executives including CEO Jeremy Sobotta and CFO Chris Scott. Participants can join via dial-in or through a live webcast, with playback available for 14 days post-call. The company focuses on enhancing cancer surgery through innovative imaging solutions, including FDA-cleared systems for real-time visualization of excised tissues.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has announced the first commercial installation of its Perimeter S-Series OCT system at Pavilion Surgery Center in Orange, California. This advanced medical imaging technology enables real-time margin visualization during surgeries, enhancing breast cancer procedures. Cleared by the FDA in 2021, the system offers 10x higher resolution than standard imaging techniques, potentially improving patient outcomes and reducing healthcare costs. Leading surgeons are already utilizing the system to ensure clean margins during surgeries.
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announces the appointment of Anantha Kancherla to its Board of Directors, effective immediately. Kancherla brings experience from leading tech firms like Microsoft and Facebook, which CEO Jeremy Sobotta believes will enhance their AI technology development. Perimeter's S-Series imaging technology is commercially available in the U.S., while the B-Series with AI is undergoing pivotal clinical trials. This leadership change comes at a crucial time for the company as it aims to innovate in cancer surgery imaging.
Perimeter Medical Imaging AI has appointed Chris Scott as the new Chief Financial Officer, effective immediately. Scott brings extensive experience in the medtech sector, having previously served as CFO at iRadimed Corporation (NASDAQ: IRMD) and successfully led them through an IPO, increasing their market cap from $10 million to $600 million. The company is well-positioned with a strong balance sheet and is focused on further developing its S-Series OCT and next-gen AI technology.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported its Q1 2022 financials, highlighting a net loss of
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) announced participation in the ROTH Canada Showcase Day on May 17, 2022, in New York, NY. The company aims to transform cancer surgery using advanced imaging tools. A presentation will be led by CEO Jeremy Sobotta at 12:00 p.m. ET. Investors can register for the webcast here.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) announced a conference call to discuss its financial results for the year ending
Perimeter Medical Imaging AI (OTC:PYNKF) reported its financial results for the year ended December 31, 2021, highlighting key developments in its commercial and clinical strategies. The Company achieved its first S-Series OCT installation, with guidance for 15-20 installations in 2022. Financially, operating expenses rose to $16.15 million, with a net loss of $16.64 million. Post-year-end, Perimeter raised approximately $48.7 million to strengthen its balance sheet. The Company is focused on ongoing clinical trials and expanding its product offerings to enhance patient outcomes.
FAQ
What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?
What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?
